Response to interferons and Apo2L of plasma cells isolated from the bone marrow of MM patients
Patient no. . | Age* (y) . | % of PCs at Dx† . | Previous treatment . | % of PCs at selection† . | % of PCs treated‡ . | Apoptosis (%) . | ||||
---|---|---|---|---|---|---|---|---|---|---|
Control . | α . | β . | γ . | Apo2L . | ||||||
1 | 66 | 80 | CTX × 6 | Clusters | 90 | 8.7 | 15 | 15 | ND | 19 |
2 | 77 | 100 | RTX × 4 | 90 | 79 | 3.2 | 26 | 22 | 8 | 53 |
3 | 69 | 80 | RTX × 4 | 51 | 80 | 9.4 | 38 | 23 | ND | 31 |
4 | 74 | 70 | RTX × 4 | 80 | 81 | 3.2 | 24 | 13 | ND | 15 |
5 | 46 | 80 | No | 80 | 100 | 5.2 | 31 | 27 | 5 | 31 |
6 | 45 | 8 | RMP, DVD × 8, CTX × 4 | ND | 90 | 5.2 | 25 | 21 | 14 | 85 |
7 | 51 | 30 | RTX × 4 | 20 | 90 | 6.3 | 36 | 34 | 17 | 86 |
8B | 44 | 60-70 | VAD × 3 | 75 | 9 | 1.9 | 2 | 13 | 4 | 11 |
CTX × 2 | ||||||||||
DVD, RTX, De, DT | ||||||||||
8C | 90 | 6.5 | 23 | 32 | 26 | 27 | ||||
9B | 61 | 55 | No | 55 | 0 | 2.7 | 2 | 4 | 1 | 5 |
9C | 85 | 2.7 | 21 | 28 | 13 | 49 | ||||
10B | 59 | 50 | No | 10-20 | 6 | 1.5 | 8 | 6 | 6 | 3 |
10C | 86 | 5.3 | 23 | 16 | 20 | 15 | ||||
5B1-153 | 46 | 80 | RTX × 2 | ND | 26 | 3.6 | ND | 7 | 10 | 5 |
5C1-153 | 92 | 6.7 | ND | 33 | 5 | 31 |
Patient no. . | Age* (y) . | % of PCs at Dx† . | Previous treatment . | % of PCs at selection† . | % of PCs treated‡ . | Apoptosis (%) . | ||||
---|---|---|---|---|---|---|---|---|---|---|
Control . | α . | β . | γ . | Apo2L . | ||||||
1 | 66 | 80 | CTX × 6 | Clusters | 90 | 8.7 | 15 | 15 | ND | 19 |
2 | 77 | 100 | RTX × 4 | 90 | 79 | 3.2 | 26 | 22 | 8 | 53 |
3 | 69 | 80 | RTX × 4 | 51 | 80 | 9.4 | 38 | 23 | ND | 31 |
4 | 74 | 70 | RTX × 4 | 80 | 81 | 3.2 | 24 | 13 | ND | 15 |
5 | 46 | 80 | No | 80 | 100 | 5.2 | 31 | 27 | 5 | 31 |
6 | 45 | 8 | RMP, DVD × 8, CTX × 4 | ND | 90 | 5.2 | 25 | 21 | 14 | 85 |
7 | 51 | 30 | RTX × 4 | 20 | 90 | 6.3 | 36 | 34 | 17 | 86 |
8B | 44 | 60-70 | VAD × 3 | 75 | 9 | 1.9 | 2 | 13 | 4 | 11 |
CTX × 2 | ||||||||||
DVD, RTX, De, DT | ||||||||||
8C | 90 | 6.5 | 23 | 32 | 26 | 27 | ||||
9B | 61 | 55 | No | 55 | 0 | 2.7 | 2 | 4 | 1 | 5 |
9C | 85 | 2.7 | 21 | 28 | 13 | 49 | ||||
10B | 59 | 50 | No | 10-20 | 6 | 1.5 | 8 | 6 | 6 | 3 |
10C | 86 | 5.3 | 23 | 16 | 20 | 15 | ||||
5B1-153 | 46 | 80 | RTX × 2 | ND | 26 | 3.6 | ND | 7 | 10 | 5 |
5C1-153 | 92 | 6.7 | ND | 33 | 5 | 31 |
PC, plasma cells; Dx, diagnosis; CTX, Cytoxan; ND, not detected; RTX, Rituxan; RMP, ritoxin + melphalan + prednisone; DVD, doxorubicin + vincristine + dexamethasone; B, C, nonplasma and plasma cells after CD138 selection; VAD, vincristine + adriamycin + doxorubicin; De, Decadron; DT, DTPASE.
PCs were isolated from the bone marrow of patients with MM by negative (patients 1-4) or positive selection. The plasma B cells (enriched more than 80%) were treated with IFN-α, β, or γ (2000 U/mL) or with Apo2L (400 ng/mL) for 48 hours. The apoptotic cells (> 200/sample) were then stained with Hoechst 33258, scored by fluorescence microscopy, and expressed as the percentage of the total cells.
Age at first diagnosis of multiple myeloma.
Identified from medical files and proved by pathologist.
Percentage of PCs in the samples treated with interferon (α, β, or γ) or with Apo2L.
This patient was seen twice: at diagnosis and 2 months later.